Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?

Study design:

The study is a parallel group, double-blind, randomised controlled clinical trial. Allocation to treatment will be made when the subject has been entered into the study that is when he/she has fulfilled the inclusion/exclusion criteria (see below). Visits will be arranged at inclusion, at week 4 and 6 (Quit day (QD)) after inclusion, and at week 1, 6, 12, and 24 after QD.

Study population:

Participants will be eligible smokers from throughout Jerusalem, who want to reduce then stop smoking.

Randomisation procedure:

Subjects will be computer-randomised either to an extended varenicline preload treatment or to a regular varenicline schedule. Both groups will receive an identical treatment thereafter.

Blinding:

Due to the nature of the intervention, blinding is possible only during the varenicline preload phase. During this phase, both the study team members and the participants will be blinded to treatment allocation. After week 6 all participants will be receiving the same, active treatment.

Study intervention:

After enrolment the subjects will be randomized to receive either varenicline preloading for 6 weeks (1 mg/day at week 1; 2 mg/day from week 2-6) (Group A) or placebo for 5 weeks and varenicline for 1 week (Group B). Then, subjects in both groups will receive regular treatment with varenicline for 12 weeks according to a schedule depicted on Table 2. Only minimal levels of advice and support will be given. However, all subjects will receive individualized verbal instructions regarding the general conduct of the study and the proper use of the study medication. All participants will be asked to reduce smoking by 50 percent during 6 weeks after inclusion then stop smoking altogether.

At baseline the following data will be collected:

• Demographic assessment (age, sex, height and weight). Subjects will be weighed during all scheduled visits on the same scale throughout the study: prior to weighing, subjects will remove shoes and excess clothes.
• Medical history
• Physical examination
• Vital signs (pulse, blood-pressure) will be assessed in the standard manner.
• Spirometry: This will be carried out at baseline and end-study using an electronic spirometer and techniques currently performed at the Pulmonary Institute, Shaare Zedek Medical Center.
• Smoking history and other smoking related information using the modified Cigarette Evaluation Questionnaire (mCEQ) .
• Nicotine dependence evaluation using the Fagerström Test for Nicotine Dependence (FTND) .
• CO in expired air. Expired carbon monoxide levels will be measured with a Bedfont monitor and recorded at each scheduled study visit. The subjects will be instructed to inhale deeply, do a 15 second breath hold, and produce a full, slow forced expiration through the disposable mouthpiece of the inflow valve of the monitor. Readings will be recorded in parts per million (ppm) of CO (non smokers = < 8 ppm ; smokers = > 10 to 75 ppm) .
• Withdrawal symptoms: Will be measured using the Mood Symptoms Physical Scale (MPPS) (See Appendix) .
• Salive Cotinine determinations: This will be carried out at 3 visits namely baseline visit, week 6 and end-trial.
• Concomitant medication: Information about currently used medication will be collected

Inclusion criteria

• Men or women aged ≥18 years
• Currently smoking 10 cigarettes per day or more
• Having smoked 5 py or more
• Presenting a CO level in expired air ≥ 10 ppm
• Personally motivated to reduce or stop smoking and indicating a willingness to follow through with protocol requirements
• Willing to sign a statement of informed consent

Exclusion criteria

• Myocardial infarction within the last 3 months
• Unstable angina
• Severe cardiac arrhythmia
• Pregnancy or breast feeding
• Use of any form of smokeless tobacco or nicotine substitution
• Having followed any smoking cessation programme during the last 3 months
• Alcohol or other drug addiction
• Use of any form of smokeless tobacco or nicotine substitution
• Participation in any clinical trial within the past 3 months
• Women in childbearing age not willing to use contraception until week 12 after QD